低剂量尿激酶治疗频发短暂性脑缺血发作的疗效

目的:观察低剂量尿激酶对频发短暂性脑缺血发作患者的疗效及安全性.方法:将38例短暂性脑缺血发作患者回顾性分为治疗组(20例)和对照组(18例),对照组给予扩张脑血管、抗凝及保护脑细胞治疗2周,治疗组在对照组基础上,加用尿激酶30万IU ivd,qd,连用3 d.比较两组患者治疗后24 h内、24～72 h及72 h后短暂性脑缺血发作控制效果,同时于治疗前及治疗结束时行血液流变学及彩色多普勒(TCD)检查.结果:治疗组治疗后24 h内、24～72 h及72 h后短暂性脑缺血发作控制效果显著优于对照组(P＜0.005);血浆黏度、纤维蛋白原、TCD检查及脉搏指数等指标均优于对照组(P＜0.05).结论:低剂量尿激酶治疗频发短暂性脑缺血发作有效且安全.

Curative Effect of Lower Dose of Urokinase in Treatment of Transient Ischemic Attacks

Objective: To observe the effect and safety in the treatment of patients with transient ischemic attacks with low dose of urokinase. Method: 38 patients with transient ischemic attacks were randomly divided into two groups: The controlled group( n = 18) , in this group,patients were treated 2 weeks by expanding blood vessel of brain, anticoagulants and protecting brain cells in the treated group (n=20) , besides the therapies of controlled group, three million units of urokinase were intravenous driped every day for three days. After the beginning, within the first 24hours,from 24 to 72 hours and 72 hours later, the effects of two groups were compared. Hemorrheology and transcranial doppler (TCD) were measured before the treatment and on the end of treatment. Result: The treated group was superior to the controlled group in the effect (P <0. 005);treated group was better than controlled group in plasma viscosity, fibrimogen level, pulse index (P < 0.05 ). Conclusion: The lower dose of urokinase was safe and well tolerated in the treatment of transient ischemic attacks patients.